Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide after HIV-associated Invasive Pneumococcal Disease

Journal of Infectious Diseases

Volumn 212, Issue 7, 2015, Pages 1093-1099

  Kantsø, Bjørn ^a   Green, Nicola ^b   Goldblatt, David ^b   Benfield, Thomas ^c,d,e  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Department of Infectious Diseases ^*  (Japan)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antibody; HAART; HIV; IPD; pneumococcal vaccines; pneumococcus; Streptococcus pneumoniae

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; PROTEIN PCPA; PROTEIN PIAA; PROTEIN PSAA; UNCLASSIFIED DRUG; ADHESIN; BACTERIUM ANTIBODY; CARRIER PROTEIN; IMMUNOGLOBULIN G; LIPOPROTEIN; PCPA PROTEIN, STREPTOCOCCUS; POLYSACCHARIDE; PSAA PROTEIN, STREPTOCOCCUS;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PREDICTION; PRIORITY JOURNAL; SEROTYPE; BLOOD; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; STREPTOCOCCUS PNEUMONIAE;

ADHESINS, BACTERIAL; ADULT; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL PROTEINS; CARRIER PROTEINS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; POLYSACCHARIDES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE;

EID: 84943368601     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv158     Document Type: Article

References (45)

1. Redd SC, Rutherford GW, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012-7.
2. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437-44.
3. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-40.
4. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4:445-55.
5. Jordano Q, Falcó V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8.
6. Harboe ZB, Larsen MV, Ladelund S, et al. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV infected individuals before and after the introduction of combination antiretroviral therapy: persisting high risk among HIV-infected injecting drug users. Clin Infect Dis 2014; 59:1168-76.
7. French N, Gordon S, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
8. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-90.
9. D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007; 21:1747-52.
10. Iwajomo OH, Finn A, Moons P, et al. Deteriorating pneumococcalspecific B-cell memory in minimally symptomatic African children with HIV infection. J Infect Dis 2011; 204:534-43.
11. Janoff EN, O'Brien J, Thompson P, et al. Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection. J Infect Dis 1993; 167:49-56.
12. Gordon SB, Miller DE, Day RB, et al. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults. J Infect Dis 2003; 188:666-70.
13. Takahashi H, Oishi K, Yoshimine H, et al. Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. Clin Infect Dis 2003; 37:1534-40.
14. Eagan R, Twigg HL, French N, et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. Clin Infect Dis 2007; 44:1632-8.
15. Kaplan JE, Benson C, Holmes K, Brooks J, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
16. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11.
17. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. AIDS 1998; 12:1683-9.
18. Bennett NM, Whitney CG, Moore M, Pilishvili T, Dooling KL. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9.
19. McCool TL, Cate TR, Tuomanen EI, Adrian P, Mitchell TJ, Weiser JN. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun 2003; 71:5724-32.
20. McCool TL, Cate TR, Moy G, Weiser JN. The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 2002; 195:359-65.
21. Henrichsen J. Six newly recognized types of Streptococcus. J Clin Microbiol 1995; 33:2759-62.
22. Sørensen UB. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol 1993; 31:2097-100.
23. Turner P, Turner C, Green N, et al. Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. Clin Microbiol Infect 2013; 19: E551-8.
24. Goldblatt D, Plikaytis BD, Akkoyunlu M, et al. Establishment of a new human pneumococcal standard reference serum, 007sp. Clin Vaccine Immunol 2011; 18:1728-36.
25. Kadioglu A,Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6:288-301.
26. Clarke VA, Platt N, Butters TD. Cloning and expression of the beta-Nacetylglucosaminidase gene from Streptococcus pneumoniae. Generation of truncated enzymes with modified aglycon specificity. J Biol Chem 1995; 270:8805-14.
27. Giefing-Kröll C, Jelencsics KE, Reipert S, Nagy E. Absence of pneumococcal PcsB is associated with overexpression of LysM domain-containing proteins. Microbiology 2011; 157(Pt 7):1897-909.
28. Ferreira DM, Neill DR, Bangert M, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013; 187:855-64.
29. Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 2005; 296:135-47.
30. Pickering JW, Martins TB, Greer RW, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 2002; 117:589-96.
31. Concepcion N, Frasch CE. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998; 5:199-204.
32. Sullivan JH, Mitchell TJ, Steinhoff MC. Antipneumolysin antibody titers in HIV-seropositive pneumococcal bacteremia. Am J Respir Crit Care Med 2001; 163:680-4.
33. Amdahl BM, Rubins JB, Daley CL, Gilks CF, Hopewell PC, Janoff EN. Impaired natural immunity to pneumolysin during human immunodeficiency virus infection in the United States and Africa. Am J Respir Crit Care Med 1995; 152:2000-4.
34. Etuwewe OM, Swann N, Hollingshead S, et al. Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titres in HIV infected adults. Vaccine 2009; 27:3881-4.
35. Ditse Z, Adrian PV, Kuwanda L, Madhi SA. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children. Vaccine 2013; 31:4421-7.
36. Scott J, Mlacha Z, Nyiro J. Diagnosis of invasive pneumococcal disease among children in Kenya with enzyme-linked immunosorbent assay for immunoglobulin G antibodies to pneumococcal. Clin Diagn Lab Immunol 2005; 12:1195-201.
37. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998; 30:597-601.
38. Simberkoff MS, El Sadr W, Schiffman G, Rahal JJ. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984; 130:1174-6.
39. French N, Moore M, Haikala R, Kayhty H, Gilks CF. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis 2004; 190:707-12.
40. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:857-62.
41. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800.
42. Hung C-C, Chang S-Y, Su C-T, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010; 11:54-63.
43. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a populationbased cohort study. PLOS Med 2009; 6:e1000081.
44. Siemieniuk RAC, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis 2011; 11:314.
45. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2002; 20:545-53.